FINWIRES · TerminalLIVE
FINWIRES

Visa Raises Fiscal 2026 Growth Outlook Following Second-Quarter Beat

作者

-- Visa (V) shares rose early Wednesday after the payments giant lifted its full-year growth outlook and reported better-than-expected fiscal second-quarter results.

The company now anticipates per-share adjusted earnings to increase by low-teens and adjusted revenue to rise by low-double-digit to low-teens, each on constant-dollar bases, for fiscal 2026, it said in a late Tuesday earnings presentation. It previously estimated both metrics to grow by low-double-digits, respectively.

The current consensus on FactSet is for non-GAAP EPS of $12.98 and sales of $45.05 billion for the fiscal year. The stock advanced 4.5% in the most recent premarket activity.

The increased revenue growth guidance reflects the company's "strong year-to-date performance" and current assumptions on "drivers, incentives, volatility and expected higher value-added services revenue growth, which incorporates the increased enthusiasm from our clients for the upcoming FIFA World Cup," Chief Financial Officer Christopher Suh said during an earnings call, according to a FactSet transcript.

Visa continues to expect broader consumer spend stability from a macro perspective, although the conflict in the Middle East has introduced uncertainty in the short term, especially related to cross-border travel spend in the Central and Eastern Europe, Middle East and Africa region, according to Suh.

The company forecasts improvements in inbound travel in the US and Latin America due to the 2026 FIFA World Cup, Suh told analysts.

For the three-month period ended March, adjusted EPS increased to $3.31 from $2.76 a year earlier, ahead of the Street's view for $3.10. Revenue rose 17% to $11.23 billion, topping the average analyst estimate of $10.75 billion. On a constant-dollar basis, revenue advanced 16% on a yearly basis.

"Consumer spending remained resilient, and our strategy and innovations fueled strong performance in consumer payments, commercial and money movement solutions and value-added services," Chief Executive Ryan McInerney said in a statement.

Visa's cross-border volume, excluding transactions within Europe, rose 11% on a constant-dollar basis. Payments volume grew 9% year over year in constant dollars, with the US logging a gain of 8%, according to Suh. Payments volume moved 10% higher in international markets, Suh said on the call.

Service revenue increased 13% to $4.98 billion while data processing revenue jumped 18% to $5.54 billion. International transaction revenue inclined 10% to $3.63 billion. Other revenue soared 41%, primarily driven by growth in advisory and other value-added services, especially marketing services revenue, as well as pricing, Suh told analysts.

For the ongoing three-month period, Visa expects adjusted EPS and net revenue to grow by mid-to-high single digits and by low double digits, respectively, in constant dollar terms. The Street is looking for non-GAAP EPS of $3.20 and sales of $11.24 billion.

相关文章

Australia

Ryde与VinaTaxi签署谅解备忘录,探索越南市场机遇

Ryde集团(RYDE)周三宣布,已与VinaTaxi签署谅解备忘录,共同探索在越南的战略合作机会。 该公司表示,合作探索的领域包括在VinaTaxi的出租车车队中部署Ryde的平台,以及开发电动摩托车出行生态系统。Price: $1.20, Change: $+0.02, Percent Change: +1.61%

$RYDE
Australia

Emergent BioSolutions 签署价值 5000 万美元的合同,为 SAB Biotherapeutics 的领先项目提供支持

Emergent BioSolutions (EBS) 周三宣布,已与 SAB Biotherapeutics (SABS) 签署一项价值 5000 万美元的多年期协议,以推进 SAB-142 的临床开发,该药物用于治疗自身免疫性 1 型糖尿病。 根据协议,其中 3600 万美元的款项取决于未来的监管审批和后续里程碑的达成情况。 Emergent BioSolutions 表示,将提供符合现行良好生产规范 (cGMP) 的端到端开发和生产服务。Price: $8.17, Change: $-0.07, Percent Change: -0.79%

$EBS$SABS
Australia

Immunome公司提交了基于3期临床试验数据的Varegacestat新药申请。

Immunome(IMNM)周三宣布,已向美国食品药品监督管理局(FDA)提交了新药申请,申请上市的药物为varegacestat,一种用于治疗成人纤维瘤的在研口服药物。 该公司表示,此次申请基于积极的3期RINGSIDE试验结果,结果显示与安慰剂相比,varegacestat显著改善了患者的无进展生存期,降低了84%的疾病进展或死亡风险,客观缓解率达到56%。 该公司补充说,试验的详细数据将在2026年美国临床肿瘤学会(ASCO)年会上公布。 Immunome股价周三下跌2.7%。Price: $23.18, Change: $-0.53, Percent Change: -2.24%

$IMNM